<DOC>
	<DOCNO>NCT00140595</DOCNO>
	<brief_summary>This study multicentric randomize trial evaluate efficacy combination ACVBP+rituximab compare combination CHOP+rituximab patient age 18 59 year diffuse large B-cell lymphoma one factor age-adjusted international prognostic index ( IPI ) .</brief_summary>
	<brief_title>ACVBP Plus Rituximab Versus CHOP Plus Rituximab Patients With Diffuse Large B-cell Lymphoma Age-adjusted IPI 1</brief_title>
	<detailed_description>This phase III multicentric open label randomize study base result previous LNH 93-5 LNH98-5 study . The LNH93-5 study show ACVBP regimen give long EFS ( 39 % vs 29 % 5 year , p=0.005 ) long overall survival ( 46 % vs 38 % 5 year , p=0.036 ) CHOP patient age 61 69 IPI score ≥1 . However ACVBP important toxicity higher treatment relate mortality ( 13 % vs 7 % , p &lt; 0.01 ) , specially 65 year . In young patient ACVBP well tolerate . The addition Rituximab standard CHOP ( R-CHOP ) show LNH98-5 study improve complete remission rate ( CR ) , event-free survival ( EFS ) overall survival ( OS ) elderly patient B-DLCL . Considering patient aa-IPI score 1 , 2 year EFS 75 % R-CHOP group compare 42 % CHOP group . This study design test whether addition rituximab ACVBP good R-CHOP patient young 60 . Primary endpoint event-free survival , expect gain 2 years-EFS 10 % R-ACVBP group compare R-CHOP group . This study multicentric , phase III open-label , randomize trial evaluate efficacy ACVBP+rituximab compare CHOP+rituximab patient age 18 59 year non previously treat diffuse large B-cell lymphoma one factor age-adjusted international prognostic index</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Patient histologically proven CD20+ diffuse large Bcell lymphoma ( WHO classification ) Aged 18 59 year . Ageadjusted International Prognostic Index equal 1 ( elevate LDH level OR stage IIIIV OR ECOG status 234 ) . Patient previously treat . With minimum life expectancy 3 month . Negative HIV , HBV HCV serologies test 4 week ( except vaccination ) . Having previously sign write informed consent . Any histological type lymphoma . Any history treat nontreated indolent lymphoma . However , patient previously diagnose diffuse large Bcell lymphoma small cell infiltration bone marrow lymph node may include . Central nervous system meningeal involvement lymphoma . Contraindication drug contain chemotherapy regimen . Any serious active disease ( accord investigator 's decision ) . Poor renal function ( creatinin level &gt; 150µmol/l ) , poor hepatic function ( total bilirubin level &gt; 30mmol/l , transaminase &gt; 2.5 maximum normal level ) unless abnormality relate lymphoma . Poor bone marrow reserve define neutrophil &lt; 1.5 G/l platelet &lt; 100 G/l , unless relate bone marrow infiltration . Any history cancer last 5 year exception nonmelanoma skin tumor stage 0 ( situ ) cervical carcinoma . Treatment investigational drug within 30 day plan first cycle chemotherapy study . Pregnant lactate woman . Adult patient tutelage .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Lymphoma , diffuse large B-cell</keyword>
	<keyword>rituximab</keyword>
	<keyword>chemotherapy</keyword>
</DOC>